Oncology

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.

With four new partners and a zero-markup model, Harrison.ai's Open Platform aims to democratize access to powerful medical AI tools for providers globally.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

MAIA Biotechnology secured a crucial $30M to advance its promising lung cancer drug, but the move sent its stock plunging amid investor fears of dilution.

With a pivotal trial for pancreatic cancer looming, Immuneering will detail its novel 'Deep Cyclic Inhibitor' platform and strategy to investors.

Peli BioThermal and Polar Group partner to upgrade Brazil's pharma logistics, tackling a booming market and ensuring safer delivery of advanced medicines.

A strategic deal between TAG1 and Dana-Farber seeks to solve a critical isotope shortage, accelerating the development of potent, targeted cancer treatments.

A new study aims to confirm a novel immunotherapy's dramatic results in colorectal cancer, offering hope for patients with limited treatment options.

Halia Therapeutics is betting on a novel target to fight chronic inflammation. At a key summit, it will pitch its unique approach for cancer, obesity, and Alzheimer's.

The biopharma company's strategic bid for non-dilutive funding could advance a first-in-class therapy for severe, untreated skin conditions.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Shareholder approval paves the way for cancer therapy innovator VERAXA to go public, aiming to accelerate its next-gen antibody-drug conjugate pipeline.

Facing delisting for being a 'public shell,' XTL Biopharma plans an appeal while its new acquisition and valuable IP hang in the balance.

With U.S. cancer centers tripling adoption of its targeted drug delivery device, RenovoRx signals a potential shift in treating solid tumors.

After securing its Nasdaq spot, TuHURA Biosciences shifts focus to its promising immuno-oncology pipeline, aiming to tackle cancer treatment resistance.

A new study shows alternating magnetic fields can destroy antibiotic-resistant biofilms on medical implants, offering hope for a non-surgical treatment.